Home › Upcoming votes › AEON Biopharma, Inc.
The deadline as the proxy statement states it: “proxies by 11:59 PM ET on December 14, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in AEON Biopharma, Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | THE REVERSE STOCK SPLIT PROPOSAL | Board | For | — |
| 2 | THE EQUITY PLAN PROPOSAL | Board | For | — |
| 3 | THE ESPP PROPOSAL | Board | For | — |
| 4 | THE ADJOURNMENT PROPOSAL Adjournment |
Board | For | — |
From AEON Biopharma, Inc.’s Form 8-K, filed January 21, 2026, for the meeting held January 21, 2026 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| 1. To approve, for purposes of complying with the NYSE American Company Guide, and for all other purposes, (i) the issuance and sale of 4,61 | 62% | — |
| 2. To approve, for purposes of complying with the NYSE American Company Guide, and for all other purposes, the exchange of the outstanding s | 62% | — |
| 3. To approve the 2023 Plan, to, among other things, increase the number of shares of Common Stock authorized for issuance thereunder (the " | 56% | — |
| 4. To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor | 60% | — |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.